← All companies
About this company
Apersys AG traces its origins to the Liver4Life project launched in 2015 through a collaboration between ETH Zurich and the University Hospital Zurich within the Wyss Translational Center Zurich. The project achieved the development of a long-term normothermic (normal body temperature) perfusion platform. This device represents a breakthrough in organ perfusion technology: It can preserve organs for 7 days, compared to the current gold standard of 6h (static cold storage) and/or 24h of competitors. In 2021, the first patient world-wide has obtained a liver transplant following 3 days organ perfusion outside the human body. In 2023, the FDA breakthrough device designation was obtained, ensuring extensive regulatory support and accelerated marketing authorization.